Corbus Pharmaceuticals Holdings, Inc. CRBP
4.00 USD +0.07 (+1.78%)
At closeNov 11, 2026, 7:11 PM EST
4.03 +0.03 +0.73%
After hours · Nov 11, 7:11 PM ET
3.80 Day range 4.19
2.86 52-week range 12.15
- YTD
- -50.86%
- 1 year
- -61.61%
News
benzinga.com RBC Capital Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $33 RBC Capital analyst Brian Abrahams maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $36 to $33.
benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $30 to $27.
benzinga.com Corbus Pharmaceuticals Q3 EPS $(1.81) Misses $(1.20) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.20) by 50.83 percent. This is a 4.74 percent increase over…
globenewswire.com Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of…
marketbeat.com Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next…
globenewswire.com Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen,…
defenseworld.net Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company,…- benzinga.com Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data from the CRB-913 Canyon-1 Phase…
globenewswire.com Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that…
globenewswire.com Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with…
zacks.com Is CRBP a Good Cannabis Investment After Positive Obesity Study Data? Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
marketbeat.com Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
benzinga.com Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity…
benzinga.com Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects' Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
benzinga.com Market-Moving News for September 14th GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest…- benzinga.com Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
globenewswire.com Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric…
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
benzinga.com Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host…
globenewswire.com Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
globenewswire.com Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the…- benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.
benzinga.com HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.- benzinga.com Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over…
- benzinga.com Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical…
globenewswire.com Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1…
globenewswire.com Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000…
globenewswire.com Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new…- benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.
benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.
marketbeat.com Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies…
seekingalpha.com Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
marketbeat.com Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic…- benzinga.com Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30 Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.
seekingalpha.com Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $40 price target.
- benzinga.com Corbus Pharma Reports Updated Data From Phase 1/2 Clinical Study Of CRB-701, Next-Gen Nectin-4 Targeted Antibody Drug Conjugate Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forwardConfirmed ORR of 42.9%…
globenewswire.com Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study…- benzinga.com Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44 Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.
- benzinga.com Corbus Pharmaceuticals To Discuss Updated Data For Its Phase 1/2 Trial Of CRB-701 Antibody Drug Candidate To Treat Head And Neck Squamous Cell Carcinoma Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team…
- benzinga.com Jefferies Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $33 Jefferies analyst Maury Raycroft maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $36 to $33.
- benzinga.com Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $54 Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $57 to $54.
- benzinga.com Guggenheim Reiterates Buy on Corbus Pharmaceuticals, Maintains $45 Price Target Guggenheim analyst Paul Jeng reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $45 price target.
benzinga.com Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over…
benzinga.com Guggenheim Initiates Coverage On Corbus Pharmaceuticals with Buy Rating, Announces Price Target of $45 Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and announces Price Target of $45.- benzinga.com Corbus Pharmaceuticals Doses Last Participant In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and…